In 2018, Sanofi-Aventis’s BSI-201 Will Garner Sales of $1.7 Billion in the Triple Negative Breast Cancer Drug Market
WALTHAM, Mass., Feb. 24 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Owing to the improvement in overall survival rates it has demonstrated in clinical trials and the need for novel targeted agents in this setting, BSI-201 is expected to steal significant market share from Roche/Genentech/Chugai’s Avastin.
The Pharmacor 2010 findings from the topic entitled Breast Cancer reveals that BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, will see considerable uptake in the treatment of triple negative breast cancer, following its launch in 2012 in the U.S. and Europe and in Japan in 2014.
In addition to BSI-201, other key PARP inhibitors in development include AstraZeneca’s Olaparib and Pfizer’s AG-014699.
“The inhibition of PARP has emerged as a novel therapeutic strategy in DNA repair-deficient tumors as studies suggest that combining PARP inhibition with DNA-damaging chemotherapy or radiation may have a synergistic or enhanced effect,” said Decision Resources Analyst Niamh Murphy, Ph.D. “Interviewed thought leaders are very optimistic about the PARP inhibitors and, in particular, about BSI-201′s potential in the triple negative breast cancer setting.”
The Pharmacor 2010 findings also reveal that recently announced clinical trial data evaluating the efficacy of trastuzumab (Roche/Genentech/Chugai’s Herceptin) in combination with lapatinib (GlaxoSmithKline/Nippon Kayaku’s Tykerb/Tyverb), provides further evidence that a dual human epidermal growth factor receptor 2 (HER2)-targeted approach improves survival for patients with HER2-positive metastatic breast cancer. However, the uptake of this combined treatment is likely to be constrained due to competition from novel HER2-targeting agents entering the market.
“We expect that the combination of trastuzumab and lapatinib will garner sales of approximately $30 million in the world’s major markets in 2013,” Dr. Murphy said. “However, in 2018, sales of trastuzumab/lapatinib will drop to less than $20 million, due to the approval and uptake of novel HER2-targeted therapies such as Roche/Genentech/Chugai’s Herceptin-DM1, Pfizer’s neratinib and Roche/Genentech/Chugai’s pertuzumab.”
About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact: Decision Resources, Inc. Christopher Comfort 781-296-2597 email@example.com
SOURCE Decision Resources